Yun Zhong
Stock Analyst at Wedbush
(0.22)
# 4,544
Out of 4,966 analysts
440
Total ratings
44.4%
Success rate
-4.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Reiterated: Buy | $10 → $13 | $6.04 | +115.23% | 12 | Sep 9, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Buy | $35 | $20.45 | +71.15% | 32 | Sep 8, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $327 | $263.52 | +24.09% | 32 | Aug 31, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $173 | $148.18 | +16.75% | 30 | Aug 31, 2026 | |
| RZLT Rezolute | Reiterated: Buy | $6 | $4.22 | +42.18% | 24 | Aug 25, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $94 | $65.68 | +43.12% | 18 | Aug 18, 2026 | |
| CAMP Camp4 Therapeutics | Reiterated: Buy | $8 | $4.25 | +88.24% | 9 | Aug 14, 2026 | |
| KLRS Kalaris Therapeutics | Rated: Buy | $17 | $3.38 | +402.96% | 4 | Aug 11, 2026 | |
| RCKT Rocket Pharmaceuticals | Rated: Buy | $16 → $15 | $3.35 | +347.76% | 23 | Aug 11, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $28 | $10.88 | +157.35% | 12 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $12.51 | +171.78% | 22 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $3.19 | +150.78% | 25 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $3.75 | +113.33% | 27 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $16 | $11.16 | +43.37% | 16 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 → $12 | $4.59 | +161.44% | 21 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $16 | $12.23 | +30.83% | 1 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 | $5.00 | +60.00% | 24 | Apr 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $28 | $2.72 | n/a | 15 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $5.02 | n/a | 14 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $38 | $44.51 | n/a | 19 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $29.05 | n/a | 13 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.52 | n/a | 7 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.28 | n/a | 9 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $8.19 | n/a | 13 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $106.20 | n/a | 9 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.15 | n/a | 3 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $15.75 | n/a | 2 | Feb 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $21.26 | n/a | 1 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $17.55 | n/a | 3 | Jun 28, 2018 |
Opus Genetics
Sep 9, 2026
Reiterated: Buy
Price Target: $10 → $13
Current: $6.04
Upside: +115.23%
Sarepta Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: $35
Current: $20.45
Upside: +71.15%
Ascendis Pharma
Aug 31, 2026
Reiterated: Buy
Price Target: $327
Current: $263.52
Upside: +24.09%
Protagonist Therapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $173
Current: $148.18
Upside: +16.75%
Rezolute
Aug 25, 2026
Reiterated: Buy
Price Target: $6
Current: $4.22
Upside: +42.18%
BioMarin Pharmaceutical
Aug 18, 2026
Reiterated: Buy
Price Target: $94
Current: $65.68
Upside: +43.12%
Camp4 Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $8
Current: $4.25
Upside: +88.24%
Kalaris Therapeutics
Aug 11, 2026
Rated: Buy
Price Target: $17
Current: $3.38
Upside: +402.96%
Rocket Pharmaceuticals
Aug 11, 2026
Rated: Buy
Price Target: $16 → $15
Current: $3.35
Upside: +347.76%
Sagimet Biosciences
Aug 11, 2026
Reiterated: Buy
Price Target: $28
Current: $10.88
Upside: +157.35%
Aug 10, 2026
Reiterated: Buy
Price Target: $34
Current: $12.51
Upside: +171.78%
Aug 7, 2026
Reiterated: Buy
Price Target: $8
Current: $3.19
Upside: +150.78%
Aug 6, 2026
Reiterated: Buy
Price Target: $8
Current: $3.75
Upside: +113.33%
Aug 4, 2026
Reiterated: Hold
Price Target: $16
Current: $11.16
Upside: +43.37%
Jul 31, 2026
Rated: Buy
Price Target: $15 → $12
Current: $4.59
Upside: +161.44%
Jul 28, 2026
Initiated Coverage: Buy
Price Target: $16
Current: $12.23
Upside: +30.83%
Apr 21, 2026
Downgraded: Hold
Price Target: $8
Current: $5.00
Upside: +60.00%
Mar 30, 2023
Rated: Buy
Price Target: $28
Current: $2.72
Upside: n/a
Mar 30, 2023
Reiterated: Hold
Price Target: n/a
Current: $5.02
Upside: n/a
Mar 28, 2023
Rated: Buy
Price Target: $38
Current: $44.51
Upside: n/a
Mar 23, 2023
Reiterated: Buy
Price Target: $4
Current: $29.05
Upside: n/a
Mar 21, 2023
Reiterated: Hold
Price Target: n/a
Current: $4.52
Upside: n/a
Mar 21, 2023
Reiterated: Buy
Price Target: $4
Current: $0.28
Upside: n/a
Mar 21, 2023
Reiterated: Buy
Price Target: $8
Current: $8.19
Upside: n/a
Jan 26, 2023
Downgraded: Hold
Price Target: n/a
Current: $106.20
Upside: n/a
May 12, 2020
Reiterated: Buy
Price Target: $10
Current: $1.15
Upside: n/a
Feb 4, 2020
Reiterated: Buy
Price Target: $14
Current: $15.75
Upside: n/a
Nov 12, 2018
Initiated Coverage: Buy
Price Target: n/a
Current: $21.26
Upside: n/a
Jun 28, 2018
Downgraded: Hold
Price Target: n/a
Current: $17.55
Upside: n/a